Overview

Raised to Date: Raised: $5,010,683

Total Commitments ($USD)

Platform

StartEngine

Start Date

09/06/2020

Close Date

10/26/2021

Min. Goal
$20
Max. Goal
$10,400,000
Min. Investment

$497

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$6.21

Pre-Money Valuation

$40,000,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

10/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$12,103

# of Investors

2,904

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2019

Industry

Fitness & Wellness

Tech Sector

Medtech

Distribution Model

B2C

Margin

Medium

Capital Intensity

High

Location

Brooklyn, New York

Business Type

Growth

Fisher Wallace Laboratories, with a valuation of $40 million, is raising funds on StartEngine through Reg A+ crowdfunding. The company manufactures and sells wearable medical devices for mood and sleep disorders, including insomnia, anxiety, and depression. The product of Fisher Wallace Laboratories, Fisher Wallace Stimulator, stimulates the brain to produce serotonin and modulates brainwave activity. Fisher Wallace Laboratories was founded by Kelly Roman and Charles Fisher. The current crowdfunding round has no minimum target and a maximum target of $10,400,000. The proceeds will be used for research and development, clinical trials, and obtaining FDA approvals. Fisher Wallace Laboratories has more than 60,000 patients and 10,000 prescribers in the US and has generated over $23.3 million in lifetime revenues.

Balance Sheet

Cash and Cash Equivalents

$339,584

Investment Securities

$0

Accounts and Notes Receivable

$30,560

Property, Plant and Equipment (PP&E)

$0

Total Assets

$459,266

Accounts Payable & Accrued Liabilities

$161,154

Long Term Debt

$576,525

Total Liabilities

$1,227,009

Total Stockholders' Equity

$-767,743

Total Liabilities and Equity

$459,266

Statement of Comprehensive Income Information

Total Revenues

$3,864,706

Costs & Expenses Applicable to Rev

$947,495

Depreciation and Amortization

$0

Net Income

$-543,056

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: IndigoSpire CPAs & Advisors
Financials as of: 09/06/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Fisher Wallace 04/17/2024 Dealmaker Securities $104,100,000 $413,448 Equity - Common Funded RegCF
Fisher Wallace 03/11/2024 Dealmaker Securities $102,658,809 $469,069 Equity - Common Funded RegCF
Fisher Wallace 01/23/2024 Dealmaker Securities $102,170,000 $532,202 Equity - Common Funded RegCF
Fisher Wallace Laboratories 10/03/2023 StartEngine $100,280,000 $493,354 Equity - Common Funded RegA+
Fisher Wallace 02/19/2023 StartEngine $81,567,588 $1,281,201 Equity - Common Funded RegCF
Fisher Wallace Laboratories 08/31/2022 StartEngine $81,236,323 $357,719 Equity - Common Funded RegCF
Fisher Wallace Laboratories 05/26/2022 StartEngine $80,048,889 $1,279,724 Equity - Common Funded RegCF
Fisher Wallace Laboratories 10/25/2021 StartEngine $40,000,000 $5,010,683 Equity - Common Funded RegA+
Fisher Wallace Laboratories 03/08/2020 StartEngine $15,000,000 $1,056,480 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

Synopsis

Even before the COVID-19 pandemic swept across the world, developed nations faced a health crisis of a different kind — a mental one. Nearly one in five adults in the United States suffers from some form of mental illness, and more than one in twenty suffer from a serious mental illness. These can range from mild depression and insomnia to suicidal depression and panic disorder. 

Modern medicine purports to treat many of these conditions through varying combinations of psychotherapy and pharmaceutical drugs. While treatment for mental illness has come a long way in the past century, this twofold approach presents a threefold challenge to consumers. First, therapy and drugs are expensive. Second, both can be of mixed effectiveness. And third, at least in the case of prescription drugs, there can be debilitating side effects that are occasionally as bad as or worse than the condition they’re intended to treat.

Returning to KingsCrowd’s Deals to Watch category for a second time, Fisher Wallace Laboratories is simplifying and cheapening treatments for mood and sleep disorders — insomnia, depression, and the like — through its Fisher Wallace Stimulator®. The neurostimulation device works by attaching wired sponges to a patient’s temples, which stimulate the patient’s brain to modulate brainwaves and produce serotonin, a neurochemical whose deficiency is linked to a variety of mental health problems.

The product, which currently retails for $799, has proven to be safe and effective in preliminary studies, with only minor side effects in a small number of patients. These early studies have shown that twenty minutes of daily use frequently leads to patient improvement within a week. Fisher Wallace Laboratories is currently engaged in three clinical trials to gain FDA approval for treatment of anxiety, depression, and insomnia, which should allow them to gain broad health insurance coverage for the product. This would make the wearable essentially free to patients and expand the company’s access to the vast health insurance market. In the meantime, Fisher Wallace Laboratories has sold more than 60,000 devices through 10,000 licensed healthcare providers. Since its previous raise in October 2019 it has moved production to a high-volume facility, reducing production costs by 60%. In the immediate future, they plan to develop a “Version 2.0” of the device while increasing sales of the current version.

Fisher Wallace Laboratories’ current StartEngine raise has been rated a Deal to Watch by the KingsCrowd investment team.

Next Section: Price

Price

Fisher Wallace Laboratories is raising on a valuation of $40 million with no discount. This remarkably high valuation is a reflection of the company’s early and impressive success in revenue and market access, as well as its access to a manufacturing process that has significantly reduced operating costs. The valuation in this raise is a significant step up from their last raise, where their valuation sat at $15 million. Despite this increase, the company has faced significant operational challenges over the past year, resulting in a decline in revenue, and the technology has yet to be definitively proven.

Next Section: Market

Market

The U.S. healthcare market is an absolutely massive one. The United States spends 17.8% of its GDP on healthcare for its residents, more per capita than any other country. This comes out to an estimated $2.48 trillion in revenue in 2019. Fisher Wallace Laboratories’ total addressable market (TAM) is somewhat smaller, but still quite large. The U.S. mental health market is sitting at $18.1 billion in 2020. Global revenues from antidepressants alone were around $14.1 billion in 2017 and are projected to reach $16.0 billion by 2023. Assuming that Fisher Wallace’s ongoing clinical trials result in FDA approval, the company may be able to start carving a sizable chunk out of this market. The company has expanded its market access beyond the U.S., getting over-the-counter approval for the product in Europe. Additionally, the planned expansion into data analysis and digital support verticals could expand its TAM.

The COVID-19 pandemic may also expand the health care market significantly, as restrictions on movement and financial strain lead to more mental health problems in the U.S. and worldwide. The neurostimulator is relatively cheap compared to long-term drug courses. It is also simple enough to operate that it can be shipped to consumers and used without professional monitoring, Fisher Wallace is well-situated to adapt to economic and logistical challenges posed by the global pandemic. 

Next Section: Team

Team

Fisher Wallace is led from the top by Kelly Roman and Charles “Chip” Fisher, who co-founded the company in the late 2000s. Both are graduates of Harvard University. Roman, CEO, has served as an executive in digital advertising and SaaS industries and brings a level of business savvy to his role. Fisher — who acquired the technology’s intellectual property and serves as chairman — is the son of Avery Fisher of Fisher Radio. He has built on that lifelong familiarity with electronics manufacturing. They make for a solid leadership team with a good track record overall as well as relevant industry experience.

Next Section: Differentiators

Differentiators

Fisher Wallace is unusual for a startup, in that it was taking in revenue even before its initial raise. It also holds patents for its Stimulator, which has FDA-clearance ahead of its approval. This heightens barriers to entry for possible competitors. With the release of Version 2.0, Fisher Wallace plans to expand their offerings with digital support services and data analytics.

While seven forms of Transcranial Magnetic Stimulation, or TMS, have been FDA-approved ahead of Fisher Wallace for similar effects, Fisher Wallace’s device is simple enough to be used directly by consumers at home. This distinction allows them to appeal directly to potential patients, which is simply not possible for manufacturers of more complex devices. Fisher Wallace’s Stimulator also shows improvement on patients with insomnia and anxiety, while TMS devices do not. Overall, Fisher Wallace’s product is well-differentiated at this time.

Next Section: Performance

Performance

In the long term, Fisher Wallace has seen tremendous progress for a startup, securing necessary patents and starting up a reliable revenue stream. The company has $23.3 million in lifetime revenues through sales to more than 60,000 patients. The securing of cheaper manufacturing processes also bodes well for future profits. It must be noted, however, that the company has faced operational challenges recently, which cut revenue down from $4.7 million of net revenue in 2018 to $3.9 million in total revenues in 2019. Fisher Wallace will need to obtain full FDA approval for its devices in order to make up for these losses and keep growing.

Next Section: Other

Bearish Outlook

Investors should bear in mind that, as of this writing, Fisher Wallace has yet to secure FDA approval for its technology. It still needs to complete its three clinical trials — while early studies have been promising, the technology is technically unproven. This means that, for now, health insurance does not cover the product — a significant obstacle to cash-strapped consumers. Should clinical trials uncover previously unnoticed side effects or a lack of effectiveness, FDA approval could be withheld, effectively tanking future sales and cutting into current revenues. Even effectiveness levels significantly lower than the preliminary results of 70% effectiveness may cut into product sales, given the availability of clinic-based TMR products that achieve similar results. The trials, for which Fisher Wallace has partnered with ProofPilot, are still ongoing, though we may see the depression study completed by the end of November.

Investors should remember that the company saw a decline in revenue last year which, while not disqualifying, is a concerning sign for an emerging technology company. Pending FDA approval and revenue declines are both risks that investors should be aware of.

Next Section: Bullish Outlook

Bullish Outlook

Fisher Wallace already has a record as a proven medical technology company and is on track to build on its early successes to deliver massive profits in the coming years. Clinical depression, insomnia, and anxiety are common maladies across the developed world. With an FDA-approval pending, the Fisher Wallace Stimulator may soon be offered to consumers across the U.S. as a cheap (insurance-covered) and more effective alternative to prescription drugs. As the company develops its Version 2.0 and expands on its offerings with digital healthcare support, it is well-positioned to carve out a slice of the $18 billion mental health care market.

Next Section: Executive Summary

Executive Summary

Fisher Wallace Laboratories has been rated a Deal to Watch because of its past and near-future successes, having established an ongoing revenue stream and a reliable product that seems likely to soon acquire FDA-approval. The company has shown an impressive rate of patient-level outreach, selling more than 60,000 units. The Stimulator is simple and easy to use by consumers at home, and its price point is cheaper than expensive prescription drug courses, even prior to FDA approval. The device may also be used in conjunction with traditional therapy and prescription drugs.

Fisher has successfully secured a manufacturing center that will reduce product costs, but as yet have not completed work on Version 2.0 of their product. Future scalability will depend on whether they can meet this milestone and continue to innovate on a user-interface side.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to support@kingscrowd.com.

Analysis written by Benjamin Potts.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Fisher Wallace Laboratories on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $40,000,000
Price per Share: $6.21

Follow company

Follow Fisher Wallace Laboratories on StartEngine

Buy Fisher Wallace Laboratories's Deal Report

Warning: according to the close date for this deal, Fisher Wallace Laboratories may no longer be accepting investments.

Fisher Wallace Laboratories Deal Report

Get KingsCrowd’s comprehensive report on Fisher Wallace Laboratories including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Fisher Wallace Laboratories is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Fisher Wallace Laboratories deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge